Neuroprotection mediated by the EP4 receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury

Neuropharmacology

Volumn 65, Issue , 2013, Pages 165-172

  Akram, Asha ^a   Gibson, Claire L ^a   Grubb, Blair D ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

COX 2; Neuroprotection; Prostaglandins; Stroke

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYL SULFOXIDE; GW 627368X; L 902688; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN SLICE; CELL DEATH; CEREBROVASCULAR ACCIDENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; BRAIN ISCHEMIA; CYCLOOXYGENASE 2 INHIBITORS; HIPPOCAMPUS; ISOINDOLES; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; RANDOM ALLOCATION; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SULFONAMIDES;

EID: 84870904245     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.09.010     Document Type: Article

References (38)

1. T. Abe, A. Kunz, M. Shimamura, P. Zhou, J. Anrather, and C. Iadecola The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic J. Cereb. Blood Flow. Metab. 29 2009 66 72
2. A.S. Ahmad, M. Ahmad, AJd Brum-Fernandes, and S. Dore Prostaglandin EP4 receptor agonist protects against acute neurotoxicity Brain Res. 1066 2005 71 77
3. A.S. Ahmad, S. Saleem, M. Ahmad, and S. Dore Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage Toxic. Sci. 89 2006 265 270
4. 2-EP3 receptors exacerbates stroke and excitotoxic injury J. Neuroimmunol. 184 2007 172 179
5. W. Clark, L. Gunion-Rinker, N. Lessov, K. Hazel, and R.L. Macdonald Citicoline treatment for experimental intracerebral hemorrhage in Mice Stroke 29 1998 2136 2140
6. K.P. Doyle, R.P. Simon, and M.P. Stenzel-Poore Mechanisms of ischemic brain damage Neuropharmacology 55 2008 310 318
7. M. Endres, U. Dirnagl, and M.A. Moskowitz The ischemic cascade and mediators of ischemic injury Handb. Clin. Neurol. 29 2009 31 41
8. S.E. Fairbrother, J.E. Smith, R.A. Broman, and H.M. Cox Characterization of the EP receptor types that mediate longitudinal smooth muscle contraction in human colon, mouse colon and mouse ileum Neurogastroenterol. Motil. 23 2011 782-e336
9. T.F. Gendron, E. Brunette, J.S. Tauskela, and P. Morley The dual role of prostaglandin E(2) in excitotoxicity and preconditioning-induced neuroprotection Eur. J. Pharmacol. 517 2005 17 27
10. C.L. Gibson, and S.P. Murphy Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice J. Cereb. Blood Flow. Metab. 24 2004 805 813
11. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 116 2006 4 15
12. K. Hattori, H. Lee, P.D. Hurn, B.J. Crain, R.J. Traystman, C. De Vries, and B.G. Lyeth Cognitive deficits after focal cerebral ischemia in mice editorial comment Stroke 31 2000 1939 1944
13. C. Iadecola, K. Niwa, S. Nogawa, X. Zhao, M. Nagayama, E. Araki, S. Morham, and M.E. Ross Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice Proc. Natl. Acad. Sci. U. S. A. 98 2001 1294 1299
14. C. Iadecola, and P.B. Gorelick The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets Stroke 36 2005 182 185
15. C.N. Joshi, S.K. Jain, and P.S.R. Murthy An optimized triphenyletetrazolium chloride method for identification of cerebral infarcts Brain Res. Prot. 13 2004 11 17
16. T. Kawano, J. Anrather, P. Zhou, L. Park, G. Wang, K.A. Frys, A. Kunz, S. Cho, M. Orio, and C. Iadecola Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity Nat. Med. 2 2006 225 229
17. A. Kunz, J. Anrather, P. Zhou, M. Orio, and C. Iadecola Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species J. Cereb. Blood Flow Metab. 273 2007 545 551
18. 4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia J. Clin. Invest. 121 2011 4362 4371
19. 2 EP2 receptor in permanent focal cerebral ischemia Ann. Neurol. 57 2005 758 761
20. A.K. Loihl, V. Asensio, I.L. Campbell, and S. Murphy Expression of nitric oxide synthase (NOS)-2 following permanent focal ischemia and the role of nitric oxide in infarct generation in male, female and NOS-2 gene-deficient mice Brain Res. 830 1 1999 155 164
21. L.J. Marnett The COXIB experience: a look in the rearview mirror Annu. Rev. Pharmacol. Toxicol. 49 2009 265 290
22. J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W.G. Smith, P.C. Isakson, and K. Seibert Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic Proc. Natl. Acad. Sci. U. S. A. 91 1994 3228 3232
23. 2 EP2 receptor in cerebral ischemia J. Neurosci. 24 2004 257 268
24. S. Nogawa, F. Zhang, M.E. Ross, and C. Iadecola Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage J. Neurosci. 17 8 1997 2746 2755
25. 4 prostanoid receptor signalling Life Sci. 74 2003 143 153
26. 2 receptor subtypes rather than cyclooxygenases: a bridge over troubled water? Mol. Interve. 6 2006 68 73
27. D.C. Rogers, C.A. Campbell, J.L. Stretton, and K.B. Mackay Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat Stroke 28 1997 2060 2066
28. 2 EP3 receptor deficient mice after cerebral ischemia J. Neuroimmunology 208 2009 87 93
29. S. Saleem, R.C. Li, G. Wei, and S. Dore Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice J. Neurosci. Res. 85 2007 2433 2440
30. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal, W.F. Stenson, A.M. Burr, W.W. Zhao, J.D. Kent, J.B. Lefkowith, K.M. Verburg, and G.S. Geis Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis J. Am. Med. Assoc. 284 2000 1247 1255
31. A.D. Simoni, and L.M. Yu Preparation of organotypic hippocampal slice cultures: interface method Nat. Protoc. 3 2006 1439 1445
32. L. Stoppini, P.A. Buchs, and D. Muller A simple method for organotypic cultures of nervous tissue J. Neurosci. Methods 37 1991 173 182
33. T. Takadera, Y. Shiraishi, and T. Ohyashiki Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons Neurochem. Int. 45 2004 713 719
34. T. Takadera, and T. Ohyashiki Prostaglandin E2 deteriorates N-methyl-D-aspartate receptor mediated cytotoxicity possibly by activating EP2 receptors in cultured cortical neurons Life Sci. 78 2006 1878 1883
35. E.J. Topol Failing the public health - rofecoxib, Merck and the FDA N. Engl. J. Med. 351 2004 1707 1709
36. H.B. Van der Worp, and J. van Gijn Clin. Prac. Acute ischemic stroke N. Engl. J. Med. 357 2007 572 579
37. 4 receptor antagonist Br. J. Pharmacol. 148 3 2006 326 339
38. R.N. Young, X. Billot, Y. Han, D.A. Slipetz, N. Chauret, M. Belley, K. Metters, M.-C. Mathieu, G.M. Greig, D. Denis, and G. Mario Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist Heterocycles 64 2004 437 446